3,6-anhydrogalactose | 224961-67-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氧环庚烷
• 英文名称: 3,6-anhydrogalactose
• 英文别名: 3,6-anhydrogalactopyranose；3,6-Anhydro-L-galactose；(1R,4R,5S,8S)-2,6-dioxabicyclo[3.2.1]octane-3,4,8-triol
• CAS: 224961-67-5
• 化学式: C₆H₁₀O₅
• 分子量: 162.142
• InChiKey: DCQFFOLNJVGHLW-YIDFTEPTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.1
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  79.2
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-(1,3-二甲基-2,6-二羰基-1,2,3,6-四氢-7H-嘌呤-7-基)-N-[(1R)-1-(羟甲基)丙基]乙酰胺 在 盐酸 作用下， 生成 3,6-anhydrogalactose
  参考文献：
  名称：

  构象对糖苷反应性的影响：葡萄糖高反应性构象体的研究

  摘要：

  构象对糖苷反应性的影响通过研究作为高反应性 (1)C(4) 构象中葡萄糖模型的 3,6-脱水糖苷的选择的水解来研究。发现甲基 3,6-脱水-β-D-吡喃葡萄糖苷比 (4)C(1) 构象中的甲基葡萄糖苷水解快 200-400 倍，而甲基 3,6-脱水-β-D-吡喃半乳糖苷，处于 B(1,4) 构象中，反应性低于甲基 β-D-吡喃半乳糖苷。甲基(3,6-脱水-β-D-吡喃葡萄糖基)-(1 --> 6)-α-D-吡喃葡萄糖苷，甲基(3,6-脱水-α-D-吡喃葡萄糖基)-(1 --> 6 )-α-D-吡喃葡萄糖基-(1 --> 6)-α-D-吡喃葡萄糖苷和甲基(3,6-脱水-β-D-吡喃葡萄糖基)-(1 --> 6)-α-D-吡喃葡萄糖基-(1 --> 6)-α-D-吡喃葡萄糖苷被制备并且发现在脱水残基处选择性地反应。糖苷的 (1)C(4) 构象异构体是高活性物种的发现符合并支持先前的结果，表明轴向

  DOI：

  10.1021/ja047476t

文献信息

• Materials for hair cosmetics and hair cosmetics
  申请人：KABUSHIKI KAISHA JAPAN HAPPY

  公开号：EP0469232A1

  公开（公告）日：1992-02-05

  The present invention provides a material for a hair cosmetic and a hair cosmetic capable of curing the hair damaged by cold permanent wave treatment, hair coloring treatment, etc. and improving the color, gloss, feel and combing smoothness of the hair. The material for hair cosmetic and the hair cosmetic contains at least one selected from among the group consisting of an extract obtained from corn grains by use of sulfurous acid water solution, water-soluble natural sugar, blood plasma or substitute blood plasma, shellac, keratin, carrageenan, a soluble cellulose, amylose, and an acrylic copolymer.

  本发明提供了一种用于头发化妆品的材料和一种头发化妆品，该材料和化妆品能够固化因冷永久波处理、染发处理等而受损的头发，并改善头发的颜色、光泽、手感和梳理顺滑度。该护发材料和护发化妆品含有至少一种选自以下组别的物质：用亚硫酸水溶液从玉米粒中提取的提取物、水溶性天然糖、血浆或替代血浆、虫胶、角蛋白、卡拉胶、可溶性纤维素、直链淀粉和丙烯酸共聚物。
• DRUGS, FOODS OR DRINKS WITH THE USE OF ALGAE-DERIVED PHYSIOLOGICALLY ACTIVE SUBSTANCES
  申请人：Takara Shuzo Co, Ltd.

  公开号：EP1038879A1

  公开（公告）日：2000-09-27

  Medicinal compositions for treating, ameliorating or preventing diseases with sensitivity to 3,6-anhydrogalactopyranose represented by formula (1): foods, drinks, cosmetics, etc. containing as the active ingredient at least one member selected from the group consisting of the above-mentioned compound, its aldehyde, its hydrate and 2-O-methylated derivatives thereof and soluble sugar compounds containing the above compound. This compound also shows, for example, an apoptosis-inducing activity, a carcinostatic activity and inhibitory activities on the production of active oxygen, lipid peroxide radicals and NO, which makes it useful also as the active ingredient of antioxidants and preservatives.

  用于治疗、改善或预防对式(1)代表的 3,6-脱水吡喃半乳糖敏感的疾病的药用组合物： 食品、饮料、化妆品等，其有效成分中至少含有一种选自上述化合物、其醛、其水合物及其 2-O-甲基化衍生物和含有上述化合物的可溶性糖类化合物组成的组。例如，这种化合物还具有诱导细胞凋亡的活性、致癌活性以及抑制活性氧、过氧化脂质自由基和 NO 生成的活性，因此也可用作抗氧化剂和防腐剂的活性成分。
• THERAPEUTIC AGENTS
  申请人：Takara Shuzo Co, Ltd.

  公开号：EP1086952A1

  公开（公告）日：2001-03-28

  Therapeutic or preventive agents for diseases requiring apoptosis induction, cancerous diseases, diseases requiring the inhibition of active oxygen production, those requiring the inhibition of nitrogen monoxide production, those requiring the inhibition of prostaglandin synthesis, those requiring the inhibition of synovial cell proliferation, those requiring the induction of heat shock protein production or those requiring the inhibition of α-glycosidase, which contain as the active ingredient compounds selected from among compounds represented by general formula (I), (wherein X and Y are each H or CH2OH, provided that when X is CH2OH, Y is H, while when X is H, Y is CH2OH), those represented by general formula (II), (wherein R is a residue obtained by freeing a compound having an SH group from the SH group) and salts of both; and foods, drinks, cosmetics and so on, containing compounds selected from among compounds of general formula (I), those of general formula (II) and salts of both.

  治疗或预防需要诱导细胞凋亡的疾病、癌症、需要抑制活性氧生成的疾病、需要抑制一氧化氮生成的疾病、需要抑制前列腺素合成的疾病、需要抑制滑膜细胞增殖的疾病、需要诱导热休克蛋白生成的疾病或需要抑制α-糖苷酶的疾病的药物、其活性成分选自通式 (I) 所代表的化合物（其中 X 和 Y 分别为 H 或 CH2OH，条件是当 X 为 CH2OH 时，Y 为 H，而当 X 为 H 时，Y 为 CH2OH）、通式 (II) 所代表的化合物（其中 R 为通过从具有 SH 基团的化合物中游离出 SH 基团而得到的残基）以及两者的盐；以及食品、饮料、化妆品等，其所含化合物选自通式（I）化合物、通式（II）化合物和两者的盐。
• MEDICINAL COMPOSITIONS
  申请人：Takara Shuzo Co, Ltd.

  公开号：EP1166786A1

  公开（公告）日：2002-01-02

  Medicinal compositions for treating or preventing diabetes, rheumatoid, diseases wherein inflammation should be inhibited, diseases wherein α-glycosidase should be inhibited, diseases wherein the synthesis of prostaglandin should be inhibited, diseases wherein endotoxin shock should be inhibited, diseases wherein the production of interleukin should be inhibited, diseases wherein the production of heme oxygenase should be induced, and diseases wherein the production of tumor necrosis factor or carcinogenesis should be inhibited, which contain as the active ingredient at least one compound selected from the group consisting of 3,6-anhydrogalactopyranose represented by formula (I), its aldehyde, its hydrate and 2-O-methylated derivatives and 2-O-sulfated derivatives thereof.

  用于治疗或预防糖尿病、类风湿、需要抑制炎症的疾病、需要抑制 α-糖苷酶的疾病、需要抑制前列腺素合成的疾病、需要抑制内毒素休克的疾 病、需要抑制白细胞介素产生的疾病的药物组合物、这些药物含有至少一种选自由式（I）代表的 3,6-脱水半乳糖、其醛、其水合物及其 2-O-甲基化衍生物和 2-O-硫酸化衍生物组成的组的化合物作为活性成分。
• MODIFIER
  申请人：TAKARA BIO INC.

  公开号：EP1362863A1

  公开（公告）日：2003-11-19

  A modifier characterized by containing as the active ingredient a compound represented by the formula (I) (wherein X is OH, OSO3H, or OCH3 and R is a substituent excluding OH). The modifier is applied to a substance having reactivity with the compound.

  一种改性剂，其特征是含有由式（I）代表的化合物作为活性成分（其中 X 是 OH、OSO3H 或 OCH3，R 是除 OH 以外的取代基）。改性剂适用于与该化合物有反应性的物质。